ArticleHuman vaccines & immunotherapeutics2025
Inequalities in HPV vaccine offer among Italian regions: Analysis of regional prevention plans.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) infection is a major cause of cervical cancer and other anogenital and oropharyngeal neoplasms. Vaccination against HPV has proven to be an effective tool in preventing these diseases. However, there are significant disparities in vaccine offer among different Italian regions. This study analyzes the vaccination strategies and offer of Italian regions for HPV vaccination, focusing on the implementation of the Italian National Vaccination Prevention Plan (PNPV) 2023-2025. Data were collected through web research. The variables examined included the availability of free vaccination for age and gender groups, catch-up strategies for unvaccinated women, and free vaccine offer for population groups with specific risk conditions. As of May 30, 2025, all regions received the PNPV 2023-2025 and formulated their vaccination regional plan accordingly. The regions showed significant variability in this process, both in the timing of the approval of the regional plan and in the offer. Differences in vaccine offer were observed by age and specific risk conditions, such as for sex workers and other sexual behaviors at risk and people with specific health conditions (e.g. non-HIV related immunosuppression). This study highlighted the need for a coordinated and uniform approach to HPV vaccination in Italy. Timely and uniform adoption of the PNPV 2023-2025 through the formulation of vaccination regional plans is crucial to reducing health inequalities and improving HPV-related health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.